APS have been shown to inhibit the EMT in hepatocellular carcinoma cells by upregulating epithelial markers such as E-cadherin and concurrently downregulating mesenchymal markers, including N-cadherin and vimentin. The gene discussed is VIM; the disease is hepatocellular carcinoma.